Page last updated: 2024-10-23

bepridil and Bleeding

bepridil has been researched along with Bleeding in 1 studies

Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.

Research Excerpts

ExcerptRelevanceReference
"In the JADER analysis, hemorrhage was significantly associated with treatment with edoxaban and verapamil (reporting odds ratio = 1."8.31Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data. ( Hosomi, K; Komatsu, Y; Takegami, M; Yodoshi, M; Yokoyama, S, 2023)
"In the JADER analysis, hemorrhage was significantly associated with treatment with edoxaban and verapamil (reporting odds ratio = 1."4.31Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data. ( Hosomi, K; Komatsu, Y; Takegami, M; Yodoshi, M; Yokoyama, S, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Komatsu, Y1
Yodoshi, M1
Takegami, M1
Yokoyama, S1
Hosomi, K1

Other Studies

1 other study available for bepridil and Bleeding

ArticleYear
Association between hemorrhage and direct oral anticoagulants in combination with verapamil: Analysis of Japanese Adverse Drug Event Report database and electronic medical record data.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:4

    Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Atrial Fibrillation;

2023